Literature DB >> 12879991

Hepatotoxicity associated with non-steroidal anti-inflammatory drugs.

Narci C Teoh1, Geoffrey C Farrell.   

Abstract

NSAIDs are one of most frequently prescribed agents in clinical practice. Whereas hepatotoxicity is a rare complication of most NSAIDs (typically 1 to 10 per 100,000 persons exposed), the high level of usage means that these drugs cause liver disease. Because of their divergent chemical structures, the mechanisms and clinicopathological manifestations of hepatotoxicity vary widely. The reactive metabolite syndrome, in which serious rash, eosinophilia, and other forms of tissue injury are common, may be incited by several NSAIDs, including newer agents. Women, people aged more than 50 years, and for some drugs, the type of arthritis, may be risk factors for drug-induced liver injury. The spectrum of NSAID-drug related hepatotoxicity continues to expand, with reports of interactive toxicity in adults with hepatitis C and recognition of rare cases of liver disease associated with non-selective, selective, and preferential COX-2 inhibitors. Better outcomes require people taking NSAIDs to be aware of possible drug reactions involving the liver, and prescribers should be vigilant for early symptoms of hepatotoxicity so that incriminated agents are discontinued promptly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879991     DOI: 10.1016/s1089-3261(03)00022-9

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  11 in total

1.  Nimesulide-induced hepatotoxicity in a previously healthy woman.

Authors:  L Gallelli; M Ferraro; G F Mauro; S De Fazio; G De Sarro
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

Review 3.  Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Authors:  Fernando Bessone
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

4.  Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs.

Authors:  Brian Yan; Yvette Leung; Stefan J Urbanski; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2006-05       Impact factor: 3.522

5.  Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases.

Authors:  Ashley R Maiuri; Anna B Breier; Lukas F J Gora; Robert V Parkins; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2015-05-07       Impact factor: 4.849

6.  Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.

Authors:  Wei Zou; Sachin S Devi; Erica Sparkenbaugh; Husam S Younis; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2008-12-12       Impact factor: 4.849

Review 7.  Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?

Authors:  Richard H Hunt; Denis Choquette; Brian N Craig; Carlo De Angelis; Flavio Habal; Gordon Fulthorpe; John I Stewart; Alexander G G Turpie; Paul Davis
Journal:  Can Fam Physician       Date:  2007-07       Impact factor: 3.275

8.  Calcium Contributes to the Cytotoxic Interaction Between Diclofenac and Cytokines.

Authors:  Ashley R Maiuri; Anna B Breier; Jonathan D Turkus; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2015-11-24       Impact factor: 4.849

9.  Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis.

Authors:  Sanford H Roth; Philip Fuller
Journal:  J Pain Res       Date:  2011-06-03       Impact factor: 3.133

Review 10.  A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.

Authors:  Philip G Conaghan
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.